These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 23020119

  • 1. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells.
    Colamartino M, Padua L, Meneghini C, Leone S, Cornetta T, Testa A, Cozzi R.
    DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119
    [Abstract] [Full Text] [Related]

  • 2. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy.
    Colamartino M, Duranti G, Ceci R, Sabatini S, Testa A, Cozzi R.
    Toxicol In Vitro; 2018 Mar; 47():1-7. PubMed ID: 29080800
    [Abstract] [Full Text] [Related]

  • 3. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
    Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, Jenner P.
    J Neural Transm (Vienna); 2002 Mar; 109(1):53-67. PubMed ID: 11793162
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.
    Colamartino M, Santoro M, Duranti G, Sabatini S, Ceci R, Testa A, Padua L, Cozzi R.
    Neurotox Res; 2015 Feb; 27(2):106-17. PubMed ID: 25355370
    [Abstract] [Full Text] [Related]

  • 5. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
    Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P.
    Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
    [Abstract] [Full Text] [Related]

  • 6. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M, Xiao AY, Kuhn W, Lehnfeld R, Waldmeier P, Sontag KH, Riederer P.
    J Neural Transm (Vienna); 2001 May; 108(2):189-204. PubMed ID: 11314772
    [Abstract] [Full Text] [Related]

  • 7. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D.
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: a comparative study of benserazide versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers.
    Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE.
    Eur Neurol; 1987 Jun; 27 Suppl 1():9-20. PubMed ID: 3123242
    [Abstract] [Full Text] [Related]

  • 9. The timing of administration, dose dependence and efficacy of dopa decarboxylase inhibitors on the reversal of motor disability produced by L-DOPA in the MPTP-treated common marmoset.
    Tayarani-Binazir KA, Jackson MJ, Fisher R, Zoubiane G, Rose S, Jenner P.
    Eur J Pharmacol; 2010 Jun 10; 635(1-3):109-16. PubMed ID: 20303948
    [Abstract] [Full Text] [Related]

  • 10. Production of Dopamine by Aromatic l-Amino Acid Decarboxylase Cells after Spinal Cord Injury.
    Ren LQ, Wienecke J, Hultborn H, Zhang M.
    J Neurotrauma; 2016 Jun 15; 33(12):1150-60. PubMed ID: 26830512
    [Abstract] [Full Text] [Related]

  • 11. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM, Kostrzewa JP, Brus R.
    Amino Acids; 2002 Jun 15; 23(1-3):57-63. PubMed ID: 12373519
    [Abstract] [Full Text] [Related]

  • 12. Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
    Zaitone SA, Hammad LN, Farag NE.
    Pharmacol Rep; 2013 Jun 15; 65(5):1213-26. PubMed ID: 24399717
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.
    Clin Neuropharmacol; 2010 May 15; 33(3):135-41. PubMed ID: 20216409
    [Abstract] [Full Text] [Related]

  • 14. Dual effects of L-DOPA on nigral dopaminergic neurons.
    Guatteo E, Yee A, McKearney J, Cucchiaroni ML, Armogida M, Berretta N, Mercuri NB, Lipski J.
    Exp Neurol; 2013 Sep 15; 247():582-94. PubMed ID: 23481547
    [Abstract] [Full Text] [Related]

  • 15. L-DOPA and glia-conditioned medium have additive effects on tyrosine hydroxylase expression in human catecholamine-rich neuroblastoma NB69 cells.
    Rodríguez-Martín E, Canals S, Casarejos MJ, de Bernardo S, Handler A, Mena MA.
    J Neurochem; 2001 Aug 15; 78(3):535-45. PubMed ID: 11483656
    [Abstract] [Full Text] [Related]

  • 16. The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.
    Lazzara CA, Riley RR, Rane A, Andersen JK, Kim YH.
    Brain Res; 2015 Oct 05; 1622():127-36. PubMed ID: 26119916
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Effect of subchronic administration of tolcapone on release of striatum dopamine and its metabolites induced by L-DOPA and carbidopa].
    Budygin EA, Gaĭnetdinov RR, Raevskiĭ KS, Mannisto PT.
    Biull Eksp Biol Med; 1998 Feb 05; 125(2):168-71. PubMed ID: 9559129
    [No Abstract] [Full Text] [Related]

  • 19. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ, Smith LA, Jackson MJ, Cheetham SC, Jenner P.
    Mov Disord; 2004 Jan 05; 19(1):15-21. PubMed ID: 14743355
    [Abstract] [Full Text] [Related]

  • 20. Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats.
    Ciesielska A, Sharma N, Beyer J, Forsayeth J, Bankiewicz K.
    PLoS One; 2015 Jan 05; 10(4):e0122708. PubMed ID: 25860990
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.